Pharmaceutica Analytica Acta

Leveraging Inter-Cellular Communication: Targeted Therapeutics through Exosome-Based Drug Delivery

Munbha Sednal^* Department of Pharmaceutics, Brigham Young University, Provo, United States of America
^*Correspondence: Munbha Sednal, Department of Pharmaceutics, Brigham Young University, Provo, United States of America, Email:

Received: 25-Sep-2023, Manuscript No. PAA-23-23866; Editor assigned: 28-Sep-2023, Pre QC No. PAA-23-23866 (PQ); Reviewed: 18-Oct-2023, QC No. PAA-23-23866; Revised: 25-Oct-2023, Manuscript No. PAA-23-23866 (R); Published: 01-Nov-2023, DOI: 10.35248/2153-2435.23.14.756

Description

Exosome-based medication delivery has become an innovative approach for targeted therapies and precision medicine. Exosomes, small extracellular vesicles naturally produced by cells, play a vital role in inter-cellular communication [1]. They contain a cargo of proteins, nucleic acids, and lipids, making them an ideal vehicle for delivering therapeutic payloads. Exosomes are nano-sized vesicles (typically 30-150 nanometers in diameter) that are secreted by various cell types, including immune cells, stem cells, and cancer cells. These tiny vesicles serve as natural carriers for bioactive molecules, and they play a critical role in inter- cellular communication. Exosomes are involved in transferring genetic information, proteins, and other biomolecules between cells, thereby influencing cellular functions and behaviors [2].

Composition of exosomes

Nucleic acids: Exosomes may carry Deoxyribonucleic Acid (DNA), Ribonucleic Acid (RNA), and microRNAs. These genetic materials can regulate gene expression in recipient cells [3].

Proteins: Exosomes contain various proteins, including enzymes, signalling molecules, and surface proteins that enable their interaction with target cells.

Lipids: Lipids within exosomes contribute to their structural integrity and can influence cellular processes [4].

Exosome-based drug delivery

Exosome-based drug delivery leverages the natural properties of these vesicles to transport therapeutic agents to specific cells or tissues.

Targeted delivery: Exosomes can be engineered to express specific targeting molecules, ensuring precise delivery to target cells or tissues [5].

Biocompatibility: Exosomes are biocompatible and less likely to trigger an immune response, reducing the risk of adverse reactions.

Stability: Exosomes protect their cargo from degradation, ensuring the integrity of the therapeutic payload until it reaches its destination [6].

Versatility: Exosomes can transport a wide range of therapeutic agents, including small molecules, nucleic acids, proteins, and even nanoparticles [7].

Applications of exosome-based drug delivery

Cancer therapy: Exosomes can be loaded with anti-cancer drugs or RNA molecules to target and inhibit the growth of cancer cells. They can also serve as carriers for cancer vaccines [8].

Neurological disorders: Exosomes are being explored for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's, as they can transport therapeutic agents across the blood-brain barrier [9].

Regenerative medicine: Stem cell-derived exosomes can stimulate tissue repair and regeneration in various medical conditions, such as cardiovascular disease and tissue injuries.

Infectious diseases: Exosomes can be engineered to deliver anti- viral or anti-bacterial agents to infected cells, potentially aiding in the treatment of infectious diseases [10].

Autoimmune disorders: Exosomes can be harnessed to modulate the immune response and treat autoimmune diseases.

Drug resistance: Exosome-based drug delivery can potentially overcome drug resistance by delivering therapeutic agents directly to resistant cells.

Conclusion

Exosome-based drug delivery represents a promising frontier in the field of therapeutics. By utilizing the natural abilities of these tiny vesicles to transport therapeutic payloads to specific cells or tissues, researchers and healthcare professionals are exploring innovative ways to target diseases with precision and minimize side effects. It's a field to follow as it continues to develop and grow because, despite continued difficulties, developments in exosome-based drug delivery give hope for more individualised and successful therapies in a variety of medical diseases.

References

1. Liu Y, Sung J, Prud’homme RK, Edwards DA. Nanoparticle of conjugated rifampicin for aerosol drug delivery and sustained release. PrincetonEdu. 2010.

   [Google Scholar]

2. Farooq U, Ahmad T, Khan A, Sarwar R, Shafiq J, Raza Y, et al. Rifampicin conjugated silver nanoparticles: A new arena for development of antibiofilm potential against methicillin resistant Staphylococcus aureus and Klebsiella pneumoniae. Int J Nanomed. 2019;29:3983-3993.

   [Crossref] [Google Scholar] [PubMed]

3. Manca ML, Sinico C, Maccioni AM, Diez O, Fadda AM, Manconi M. Composition influence on pulmonary delivery of rifampicin liposomes. Pharmaceutics. 2012;4(4):590-606.

   [Crossref] [Google Scholar] [PubMed]

4. Jayan H, Leena MM, Sundari SS, Moses JA, Anandharamakrishnan C. Improvement of bioavailability for resveratrol through encapsulation in zein using electrospraying technique. J Funct Foods. 2019;57:417-424.

   [Crossref] [Google Scholar]

5. Vicente E, Pérez-Silanes S, Lima LM, Ancizu S, Burguete A, Solano B, et al. Selective activity against Mycobacterium tuberculosis of new quinoxaline 1, 4-di-N-oxides. Bioorganic Med Chem. 2009;17(1):385-389.

   [Crossref] [Google Scholar] [PubMed]

6. Mali AJ, Pawar AP, Purohit RN. Development of budesonide loaded biopolymer based dry powder inhaler: Optimization, in vitro deposition, and cytotoxicity study. J Pharm. 2014;1–12.

   [Crossref] [Google Scholar] [PubMed]

7. Nahata MC, Pai VB. Pediatric drug formulations. Whitney Books: Harvey.2014.
8. Sklubalová Z, Zahálka L, Matysová L, Klovrzová S, Petrelová M, Horák P, et al. 3PC-008 Formulation and stability study of the extemporaneous oral solutions of cardiologic drugs for personalised therapy of newborns. 2018. 25(S1):A27-A27.

   [Crossref] [Google Scholar]

9. Svirskis D, Jaffer J, Agarwal P, Khan A, Kaur J, Cheng A, et al. Alcoholfree extemporaneous formulations of furosemide are chemically and physically stable in ora-blend products for 30 days. Int J Pharm Compd. 2020;24(3):246-251.

   [Google Scholar] [PubMed]

10. Zahálka L, Klovrzová S, Matysová L, Šklubalová Z, Solich P. Furosemide ethanol-free oral solutions for paediatric use: Formulation, HPLC method and stability study. Eur J Hosp Pharm. 2018;25(3):144-149.

    [Crossref] [Google Scholar] [PubMed]